

Sebastian Grosicki

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8446885/publications.pdf>

Version: 2024-02-01

93
papers

8,509
citations

185998

28
h-index

45213

90
g-index

94
all docs

94
docs citations

94
times ranked

6665
citing authors

#	ARTICLE	IF	CITATIONS
1	Nutritional status of patients with lymphoproliferative neoplasms before and after the first-line treatment. <i>Expert Review of Hematology</i> , 2022, 15, 83-91.	1.0	1
2	Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. <i>Blood Advances</i> , 2022, 6, 3440-3450.	2.5	91
3	Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	7
4	Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2022, 9, e403-e414.	2.2	23
5	Tracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing. <i>Biomedicines</i> , 2022, 10, 1674.	1.4	3
6	Heterogenous mutation spectrum and deregulated cellular pathways in aberrant plasma cells underline molecular pathology of light-chain amyloidosis. <i>Haematologica</i> , 2021, 106, 601-604.	1.7	2
7	Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial. <i>British Journal of Haematology</i> , 2021, 194, 132-139.	1.2	13
8	Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2021, 14, 59.	6.9	11
9	Umbralisib, a Dual PI3K/CK1 Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 1609-1618.	0.8	111
10	Multiple myeloma triplet therapies: baseline characteristics and control groups – Authors' reply. <i>Lancet</i> , 2021, 397, 1621-1623.	6.3	1
11	IDH2 mutations in patients with normal karyotype AML predict favorable responses to daunorubicin, cytarabine and cladribine regimen. <i>Scientific Reports</i> , 2021, 11, 10017.	1.6	3
12	Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. <i>American Journal of Hematology</i> , 2021, 96, 708-718.	2.0	16
13	Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy. <i>British Journal of Haematology</i> , 2021, 194, 784-788.	1.2	7
14	Elotuzumab in the treatment of relapsed and refractory multiple myeloma. <i>Future Oncology</i> , 2021, 17, 1581-1591.	1.1	6
15	Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial. <i>BMC Cancer</i> , 2021, 21, 659.	1.1	8
16	Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 785-798.	0.2	22
17	Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , 2021, 22, 801-812.	5.1	162
18	Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone. <i>American Journal of Hematology</i> , 2021, 96, E383-E386.	2.0	7

#	ARTICLE	IF	CITATIONS
19	Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk. <i>American Journal of Hematology</i> , 2021, 96, 1120-1130.	2.0	15
20	Cladribine Combined with Low-Dose Cytarabine as Frontline Treatment for Unfit Elderly Acute Myeloid Leukemia Patients: Results from a Prospective Multicenter Study of Polish Adult Leukemia Group (PALG). <i>Cancers</i> , 2021, 13, 4189.	1.7	6
21	Incidence of central nervous system relapses in patients with DLBCL treated with lenalidomide as maintenance after R-CHOP. <i>Blood Advances</i> , 2021, 5, 2965-2968.	2.5	8
22	A Phase 1b/2 Study of Navtemadlin (KRT-232), a Murine Double Minute 2 Inhibitor, Combined with a BCR-ABL Tyrosine Kinase Inhibitor in Patients with Relapsed/Refractory, <i>t(15;17)TP53</i> WT, Ph+ Chronic Myeloid Leukemia. <i>Blood</i> , 2021, 138, 2562-2562.	0.6	2
23	Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study. <i>Blood</i> , 2021, 138, 3793-3793.	0.6	6
24	Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. <i>Leukemia</i> , 2020, 34, 787-798.	3.3	321
25	Outcome of a Real-Life Population of Patients With Acute Promyelocytic Leukemia Treated According to the PETHEMA Guidelines: The Polish Adult Leukemia Group (PALG) Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 105-113.	0.2	3
26	Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study. <i>British Journal of Haematology</i> , 2020, 189, 84-96.	1.2	15
27	Early induction intensification with cladribine, cytarabine, and mitoxantrone (CLAM) in AML patients treated with the DAC induction regimen: a prospective, non-randomized, phase II study of the Polish Adult Leukemia Group (PALG). <i>Leukemia and Lymphoma</i> , 2020, 61, 588-603.	0.6	1
28	Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. <i>Lancet, The</i> , 2020, 395, 132-141.	6.3	299
29	Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. <i>Blood Cancer Journal</i> , 2020, 10, 91.	2.8	90
30	Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial. <i>Blood Advances</i> , 2020, 4, 6009-6018.	2.5	57
31	Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. <i>Lancet, The</i> , 2020, 396, 1563-1573.	6.3	188
32	<p></p>Mean Platelet Volume Has Prognostic Value in Chronic Lymphocytic Leukemia</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 9977-9985.	0.9	8
33	Refeeding syndrome in hematological cancer patients – current approach. <i>Expert Review of Hematology</i> , 2020, 13, 201-212.	1.0	4
34	A 5-year follow-up to evaluate the efficacy and safety of ofatumumab added to fludarabine and cyclophosphamide in patients with relapsed chronic lymphocytic leukemia: final analysis of the COMPLEMENT 2 trial. <i>Leukemia and Lymphoma</i> , 2020, 61, 1748-1751.	0.6	2
35	Heat shock proteins as a new, promising target of multiple myeloma therapy. <i>Expert Review of Hematology</i> , 2020, 13, 117-126.	1.0	7
36	A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma. <i>American Journal of Hematology</i> , 2020, 95, 503-509.	2.0	11

#	ARTICLE	IF	CITATIONS
37	Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1. <i>Haematologica</i> , 2020, 105, 2440-2447.	1.7	31
38	Five-year survival follow-up of a phase III randomised trial comparing ofatumumab versus physicians' choice for bulky fludarabine-refractory chronic lymphocytic leukaemia: a short report. <i>British Journal of Haematology</i> , 2020, 189, 689-693.	1.2	0
39	Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2020, 7, e370-e380.	2.2	170
40	A five-year follow-up of untreated patients with chronic lymphocytic leukaemia treated with ofatumumab and chlorambucil: final analysis of the Complement 1 phase 3 trial. <i>British Journal of Haematology</i> , 2020, 190, 736-740.	1.2	9
41	Umbralisib, the Once Daily Dual Inhibitor of PI3K γ and Casein Kinase-1 μ Demonstrates Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: Results from the Phase 2 Global Unity-NHL Trial. <i>Blood</i> , 2020, 136, 34-35.	0.6	8
42	Final Analysis of the International Double-Blind Randomized Phase III Study of Lenalidomide Maintenance in Elderly Patients with DLBCL in Response after R-CHOP, the Remarc Study from Lysa. <i>Blood</i> , 2020, 136, 1-2.	0.6	1
43	Lenalidomide As Maintenance Therapy after R-CHOP Has No Protecting Effect for Central Nervous System Relapse in Frontline Treatment of Diffuse Large B-Cells Lymphoma. an Ancillary Studies of the Remarc Study. <i>Blood</i> , 2020, 136, 22-23.	0.6	2
44	Impact of Prior Therapies on the Safety and Efficacy of Once Weekly Selinexor, Bortezomib, and Dexamethasone Compared with Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Results from the Boston Study. <i>Blood</i> , 2020, 136, 50-52.	0.6	1
45	DREAMM-7: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin (Belamaf) with Bortezomib, and Dexamethasone (B-Vd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2020, 136, 53-54.	0.6	13
46	Demyelinating polyneuropathy and lymphoplasmacytic lymphoma coexisting in 36-year-old man: A case report. <i>World Journal of Clinical Cases</i> , 2020, 8, 2566-2573.	0.3	1
47	The impact of cytogenetic evolution and acquisition of del(17p) on the prognosis of multiple myeloma patients. <i>Polish Archives of Internal Medicine</i> , 2020, 130, 483-491.	0.3	3
48	Progression-Free Survival (PFS) Benefit Demonstrated and Quality of Life (QoL) Maintained across Age and Frailty Subgroups with the Oral Proteasome Inhibitor (PI) Ixazomib Vs Placebo As Post-Induction Maintenance Therapy in Non-Transplant Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Analysis of the TOURMALINE-MM4 Phase 3 Trial. <i>Blood</i> , 2020, 136, 30-31.	0.6	6
49	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. <i>Lancet</i> , 2019, 394, 2096-2107.	6.3	435
50	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , 2019, 20, 781-794.	5.1	254
51	Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study. <i>Blood Cancer Journal</i> , 2019, 9, 98.	2.8	11
52	All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. <i>European Journal of Cancer</i> , 2019, 106, 89-98.	1.3	25
53	Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. <i>New England Journal of Medicine</i> , 2018, 378, 518-528.	13.9	747
54	Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2018, 379, 1811-1822.	13.9	413

#	ARTICLE	IF	CITATIONS
55	Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies. <i>American Journal of Hematology</i> , 2018, 93, 1402-1410.	2.0	24
56	Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. <i>Haematologica</i> , 2018, 103, 1502-1510.	1.7	111
57	One-Year Update of a Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Patients (Pts) with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): Alcyone. <i>Blood</i> , 2018, 132, 156-156.	0.6	20
58	Extended 5-y follow-up (FU) of phase 3 ELOQUENT-2 study of elotuzumab + lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , 2018, 36, 8040-8040.	0.8	10
59	Evaluation on inflammatory states of peripheral veins connected with cannulation /. <i>Przegląd Epidemiologiczny</i> , 2018, 72, 205-213.	0.4	0
60	Addition of cladribine to the standard induction treatment improves outcomes in a subset of elderly acute myeloid leukemia patients. Results of a randomized Polish Adult Leukemia Group (PALG) phase II trial. <i>American Journal of Hematology</i> , 2017, 92, 359-366.	2.0	24
61	Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: <sc>ELOQUENT</sc> follow-up and <i>post-hoc</i> analyses on progression-free survival and tumour growth. <i>British Journal of Haematology</i> , 2017, 178, 896-905.	1.2	120
62	Similar survival outcomes in patients with biclonal versus monoclonal myeloma: a multi-institutional matched case-control study. <i>Annals of Hematology</i> , 2017, 96, 1693-1698.	0.8	7
63	Health-related quality of life and patient-reported outcomes of ofatumumab plus fludarabine and cyclophosphamide versus fludarabine and cyclophosphamide in the COMPLEMENT 2 trial of patients with relapsed CLL. <i>Leukemia and Lymphoma</i> , 2017, 58, 1598-1606.	0.6	11
64	Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial. <i>Leukemia and Lymphoma</i> , 2017, 58, 1084-1093.	0.6	48
65	Phase 3 ELOQUENT-2 study: Extended four year follow-up (FU) of elotuzumab plus lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , 2017, 35, 8028-8028.	0.8	5
66	Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study. <i>British Journal of Haematology</i> , 2016, 175, 884-891.	1.2	21
67	Cladribine added to daunorubicin-cytarabine induction prolongs survival of FLT3-ITD+ normal karyotype AML patients. <i>Blood</i> , 2016, 127, 360-362.	0.6	34
68	Elotuzumab: a novel immune-stimulating therapy to treat multiple myeloma. <i>Expert Review of Hematology</i> , 2016, 9, 621-628.	1.0	3
69	Phase III, randomized study of ofatumumab versus physicians'™ choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2016, 57, 2037-2046.	0.6	20
70	11q Deletion (del11q) Is Not a Prognostic Factor for Adverse Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Ibrutinib: Pooled Data from 3 Randomized Phase 3 Studies. <i>Blood</i> , 2016, 128, 2042-2042.	0.6	9
71	Cladribine, Cytarabine and Mitoxantrone As Treatment Intensification for Patients with Acute Myeloid Leukemia with the Excess of Bone Marrow Blasts on Day 14 of the First Induction. Prospective, Multicenter Study By the Polish Adult Leukemia Group (PALG). <i>Blood</i> , 2016, 128, 213-213.	0.6	1
72	Analysis of occupational exposures to blood registered in the General Hospital in Zabrze in the years 2006-2015. <i>Przegląd Epidemiologiczny</i> , 2016, 70, 603-615.	0.4	2

#	ARTICLE	IF	CITATIONS
73	Szpiczak plazmocytowy z niewydolnością nerek jako wyzwanie terapeutyczne. <i>Acta Haematologica Polonica</i> , 2015, 46, 80-85.	0.1	1
74	Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study. <i>Haematologica</i> , 2015, 100, e207-e210.	1.7	31
75	Assessing the efficacy of allogeneic hematopoietic stem cells transplantation (allo-HSCT) by analyzing survival end points in defined groups of acute myeloid leukemia patients: A retrospective, multicenter Polish Adult Leukemia Group study. <i>American Journal of Hematology</i> , 2015, 90, 904-909.	2.0	4
76	Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2015, 373, 621-631.	13.9	1,139
77	Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2015, 373, 2425-2437.	13.9	1,261
78	Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. <i>Lancet, The</i> , 2015, 385, 1873-1883.	6.3	296
79	Ofatumumab for the treatment of chronic lymphocytic leukemia. <i>Expert Review of Hematology</i> , 2015, 8, 265-272.	1.0	6
80	CEBPA copy number variations in normal karyotype acute myeloid leukemia: Possible role of breakpoint-associated microhomology and chromatin status in CEBPA mutagenesis. <i>Blood Cells, Molecules, and Diseases</i> , 2015, 55, 284-292.	0.6	3
81	Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. <i>Lancet Oncology, The</i> , 2015, 16, 1370-1379.	5.1	105
82	Bortezomib for the treatment of multiple myeloma. <i>Expert Review of Hematology</i> , 2014, 7, 173-185.	1.0	17
83	Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. <i>Blood</i> , 2014, 123, 4136-4142.	0.6	125
84	Gene Mutations and Treatment Outcome in CLL Patients Treated with Chlorambucil (Chl) or Ofatumumab-Chl (O-Chl): Results from the Phase III Study COMPLEMENT1 (OMB110911). <i>Blood</i> , 2014, 124, 1992-1992.	0.6	4
85	Ofatumumab (OFA) Vs. Physician's Choice (PC) of Therapy in Patients (pts) with Bulky Fludarabine Refractory (BFR) Chronic Lymphocytic Leukaemia (CLL): Results of the Phase III Study OMB114242. <i>Blood</i> , 2014, 124, 4684-4684.	0.6	6
86	NOTCH1 Mutation and Treatment Outcome In CLL Patients Treated With Chlorambucil (Chl) Or Ofatumumab-Chl (O-Chl): Results From The Phase III Study Complement 1 (OMB110911). <i>Blood</i> , 2013, 122, 527-527.	0.6	9
87	Ofatumumab + Chlorambucil Versus Chlorambucil Alone In Patients With Untreated Chronic Lymphocytic Leukemia (CLL): Results Of The Phase III Study Complement 1 (OMB110911). <i>Blood</i> , 2013, 122, 528-528.	0.6	49
88	Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. <i>Haematologica</i> , 2012, 97, 1925-1928.	1.7	119
89	Cladribine, But Not Fludarabine, Added to Daunorubicin and Cytarabine During Induction Prolongs Survival of Patients With Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 2441-2448.	0.8	214
90	Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. <i>Lancet Oncology, The</i> , 2011, 12, 431-440.	5.1	835

#	ARTICLE	IF	CITATIONS
91	The early reduction of leukemic blasts in bone marrow on day 6 of induction treatment is predictive for complete remission rate and survival in adult acute myeloid leukemia; The results of multicenter, prospective Polish adult leukemia group study. <i>American Journal of Hematology</i> , 2011, 86, 437-439.	2.0	12
92	Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group. <i>European Journal of Haematology</i> , 2008, 80, 115-126.	1.1	122
93	Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome – Polish Adult Leukemia Group (PALG) pilot study. <i>Annals of Hematology</i> , 2008, 87, 361-367.	0.8	12